asxan.ai Agents Hub

Boswellia serrata

Evidence Fact Sheet

Indian frankincense · boswellic acids

Boswellia serrata (Indian frankincense) is a botanical whose boswellic acids — notably AKBA — act as non-redox 5-LOX inhibitors that suppress leukotriene synthesis. Studied for joint comfort, GI-inflammation markers, and respiratory function. Research dose is typically standardized extract ~900–1500 mg/day (AKBA-enriched branded extracts 100–250 mg/day). US DSHEA supplement; no authorized EFSA health claim.

Also known as: Boswellia · Boswellia serrata · Indian frankincense · Salai guggal · Boswellic acids · AKBA (3-O-acetyl-11-keto-β-boswellic acid) · Aflapin® · 5-Loxin® · Boswellin® · AprèsFlex®

Overview

Boswellia serrata (Indian frankincense, "Salai guggal") is a gum-resin botanical standardized to boswellic acids, of which 3-O-acetyl-11-keto-β-boswellic acid (AKBA) is the most-studied active. Mechanistically it is characterized as a non-redox, selective 5-lipoxygenase (5-LOX) inhibitor that suppresses leukotriene biosynthesis, with additional reported NF-κB/IKK pathway inhibition in research contexts. Generic-extract research typically uses standardized extract around 300–500 mg three times daily (~900–1500 mg/day), while AKBA-enriched branded extracts (Aflapin, 5-Loxin) have been studied at roughly 100–250 mg/day; cerebral-edema radiotherapy-adjunct research used higher doses. In the US it is a dietary-supplement ingredient under DSHEA (structure/function claims only); the EU has no authorized EFSA health claim, Brazil regulates it as a traditional phytomedicine, and China treats it as a TCM herbal material rather than a food ingredient. This page reports research findings in studied populations and is educational, not medical or dosing advice.

Mechanism of Action

AKBA selective 5-LOX (5-lipoxygenase) inhibition (non-redox) · Leukotriene (LTB4/LTC4/LTD4) synthesis suppression · NF-κB pathway inhibition via IKK blockade · Pro-inflammatory cytokine downregulation (TNF-α / IL-1β / IL-6) · MMP-3/MMP-9 downregulation (cartilage-matrix protection · research context)

Body systems: Musculoskeletal · Immune System · Digestive & Gut · Respiratory & Mucosal Barrier

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Boswellia serrata is not characterized as a treatment for any disease.

Osteoarthritis — Pain & Function (Pooled)

Meta-analysis supported
  • 7 trials · 545 patientspooled sample
  • WMD -8.33VAS pain · P<0.00001
  • WMD -10.75WOMAC function · P<0.00001

In a meta-analysis pooling seven randomized trials of osteoarthritis patients, Boswellia and its extract were associated with statistically significant reductions in pain, stiffness, and physical function versus control. This is the strongest joint-comfort evidence on the card, framed as a research finding in OA populations rather than a treatment claim.

Reported effect: Seven trials involving 545 patients were included; VAS WMD -8.33 (95% CI -11.19, -5.46; P<0.00001); WOMAC pain WMD -14.22 (95% CI -22.34, -6.09; P=0.0006); WOMAC stiffness WMD -10.04 (95% CI -15.86, -4.22; P=0.0007); WOMAC function WMD -10.75 (95% CI -15.06, -6.43; P<0.00001).

“Seven trials involving 545 patients were included. VAS: WMD -8.33; 95% CI -11.19, -5.46; P<0.00001. WOMAC pain: WMD -14.22; 95% CI -22.34, -6.09; P = 0.0006. WOMAC stiffness: WMD -10.04; 95% CI -15.86, -4.22; P = 0.0007. WOMAC function: WMD -10.75; 95% CI -15.06, -6.43; P<0.00001.”

Source: PMID 32680575 · Yu 2020 · BMC Complement Med Ther

Osteoarthritis — Standardized Extract (Aflapin Subgroup)

Meta-analysis supported
  • 9 RCTs · 712 participantspooled sample
  • MD -10.71VAS pain · p<0.00001
  • MD -5.49WOMAC stiffness · p<0.00001

A separate systematic review and sub-group meta-analysis of nine RCTs found Boswellia serrata supplementation significantly improved VAS pain, Lequesne index, and WOMAC pain/stiffness/function versus control, with the AKBA-enriched branded extract (Aflapin) showing larger effects in the subgroup. Reported as a research finding in OA populations.

Reported effect: 9 randomized controlled trials involving 712 participants; VAS MD -10.71 (p<0.00001); LFI MD -2.99 (p<0.00001); WOMAC-pain MD -10.69 (p<0.0001); WOMAC-stiffness MD -5.49 (p<0.00001); WOMAC-function MD -10.69 (p<0.00001).

“Systematic review and meta-analysis of 9 randomized controlled trials involving 712 participants... VAS: MD -10.71; p<0.00001. LFI: MD -2.99; p<0.00001. WOMAC-pain: MD -10.69; p<0.0001. WOMAC-stiffness: MD -5.49; p<0.00001. WOMAC-function: MD -10.69; p<0.00001. BS supplementation is effective OA symptomatic management.”

Source: PMID 38365549 · Dubey 2024 · Explore (NY)

Ulcerative Colitis — Remission Markers

RCT supported
  • 82% remissionBoswellia gum resin
  • 75% remissionsulfasalazine control
  • 350 mg ×3/daydose · 6 weeks

In a controlled study of ulcerative colitis patients, Boswellia serrata gum resin (350 mg three times daily for 6 weeks) produced a remission rate numerically comparable to the sulfasalazine comparator. This is an early, small GI-inflammation finding in a disease population; the abstract reports proportions but no inferential test, so treat it as directional.

Reported effect: 82% out of treated patients went into remission; in case of sulfasalazine remission rate was 75%. Dose: 350 mg of Boswellia serrata gum resin three times daily for 6 weeks.

“350 mg of Boswellia serrata gum resin administered three times daily for 6 weeks... 82% out of treated patients went into remission; in case of sulfasalazine remission rate was 75%.”

Source: PMID 9049593 · Gupta 1997 · Eur J Med Res

Bronchial Asthma — Symptom Improvement

RCT supported
  • 70% improvedBoswellia group
  • 27% improvedcontrol group
  • n=80 · 300 mg ×3/day6-week trial

In a double-blind, placebo-controlled 6-week trial of 80 bronchial-asthma patients, 70% improved on Boswellia serrata gum resin (300 mg three times daily) versus 27% on control, with reported changes in dyspnoea, attack frequency, FEV1, FVC, PEFR and eosinophil count. A respiratory-function research finding in a disease population, not a treatment claim.

Reported effect: 80 patients (40 treatment, 40 control); 300 mg thrice daily for 6 weeks; 70% of patients showed improvement of disease in the Boswellia group vs only 27% of patients in the control group.

“300 mg thrice daily for a period of 6 weeks... 70% of patients showed improvement of disease [Boswellia group], while Only 27% of patients in the control group showed improvement.”

Source: PMID 9810030 · Gupta 1998 · Eur J Med Res

Cerebral Edema — Radiotherapy Adjunct (Brain Tumor)

RCT supported
  • 60% vs 26%>75% edema reduction · P=.023
  • 4200 mg/daydose

In a randomized, placebo-controlled pilot trial of 44 patients irradiated for malignant cerebral tumors, a >75% reduction in cerebral edema occurred in 60% receiving Boswellia serrata (4200 mg/day) versus 26% on placebo. A high-dose, specialized oncology-adjunct research context — included to show the breadth of evidence, not as general supplement guidance.

Reported effect: Forty-four patients with primary or secondary malignant cerebral tumors were randomly assigned to radiotherapy plus either BS 4200 mg/day or placebo; a reduction of cerebral edema of >75% was found in 60% of patients receiving BS and in 26% of patients receiving placebo (P = .023).

“Forty-four patients with primary or secondary malignant cerebral tumors were randomly assigned... radiotherapy plus either BS 4200 mg/day or placebo... a reduction of cerebral edema of >75% was found in 60% of patients receiving BS and in 26% of patients receiving placebo (P = .023).”

Source: PMID 21287538 · Kirste 2011 · Cancer

Crohn's Disease — Maintenance of Remission (Honest Negative)

Null / no benefit RCT supported

Honest negative: in a randomized, placebo-controlled, double-blind trial of 82 Crohn's disease patients, Boswellia (Boswelan) did not outperform placebo for maintaining remission — remission rates and time to relapse were statistically indistinguishable. Safety was good but efficacy was not demonstrated, a key counterweight to the positive GI signals.

Effect size: not quantified on this page — see the linked study below for the reported figures.

Source: PMID 20848527 · Holtmeier 2011 · Inflamm Bowel Dis

Dosage (research context · not a recommendation)

Standardized extract 300-500 mg three times daily (≈900-1500 mg/day) in generic-extract OA research; AKBA-enriched branded extracts (Aflapin® / 5-Loxin®) studied at 100-250 mg/day — a notable low-dose advantage; cerebral-edema radiotherapy-adjunct research used up to 4200 mg/day. Educational reference, not a dosing recommendation. Note (branded-extract caveat): low-dose 100 mg/day data applies ONLY to the branded AKBA-enriched extracts, not to generic resin powder.

Regulatory Status · 4 Markets

US · FDA
US dietary supplement ingredient under DSHEA · structure/function claims (joint health, healthy inflammatory response, joint flexibility). Branded extracts Aflapin®/5-Loxin® hold self-affirmed GRAS + NDI notifications; Boswellin® (Sabinsa) + AprèsFlex® (PLT) hold NDI. Boswellia serrata Extract is USP-NF monographed (AKBA assay). All S/F claims require the FDA disclaimer: 'This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.'
EU · EFSA
No authorized EFSA health claim — Article 13.1 joint-health / anti-inflammatory / respiratory claims were returned (2009: cause-effect not established, human RCT data deemed insufficient at that time). Not a Novel Food. Traditional Herbal Medicinal Product (THR) registration is available in some member states (Germany BfArM accepts traditional-use registration under Directive 2004/24/EC).
CN · China
No confirmed China supplement/food status: Boswellia is a TCM herbal material (Chinese Pharmacopoeia 2020), not a novel food ingredient and not permitted in conventional foods; no health-food registration exists.
BR · ANVISA
Regulated as a traditional phytomedicine (Fitoterápico / Produto Tradicional Fitoterápico), NOT as a dietary supplement (Suplemento Alimentar) — Boswellia serrata is on the IN 02/2014 Anexo I positive list under RDC 26/2014. Approved traditional use: anti-inflammatory (anti-inflamatório); standardized total boswellic acids typically ≥60%. Requires Fitoterápico Tradicional registration (~6-12 months) + local regulatory agent.

Safety

Generally well tolerated up to ~1000 mg/day for 6 months in trials; most common effect is mild GI upset (nausea, acid reflux, diarrhea, <5%); rash rare. Theoretical mild antiplatelet/anticoagulant interaction (warfarin/aspirin) — clinical reports very rare; consider stopping ~2 weeks before surgery. In-vitro weak CYP2C8/2C9 inhibition by AKBA (clinical significance unclear). Inadequate pregnancy/lactation data — consult a healthcare provider. Branded vs generic clinical data must not be conflated. Educational, not medical advice.

Goals: joint-bone · inflammation-relief

Lifestyles: senior-60-plus

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

  1. PMID 32680575 · Yu 2020 · BMC Complement Med Ther — Osteoarthritis — Pain & Function (Pooled)
  2. PMID 38365549 · Dubey 2024 · Explore (NY) — Osteoarthritis — Standardized Extract (Aflapin Subgroup)
  3. PMID 9049593 · Gupta 1997 · Eur J Med Res — Ulcerative Colitis — Remission Markers
  4. PMID 9810030 · Gupta 1998 · Eur J Med Res — Bronchial Asthma — Symptom Improvement
  5. PMID 21287538 · Kirste 2011 · Cancer — Cerebral Edema — Radiotherapy Adjunct (Brain Tumor)
  6. PMID 20848527 · Holtmeier 2011 · Inflamm Bowel Dis — Crohn's Disease — Maintenance of Remission (Honest Negative)

Frequently Asked Questions

1. What is boswellia and how is it thought to work?

Boswellia serrata (Indian frankincense) is a gum-resin botanical standardized to boswellic acids. Its most-studied active, AKBA, is characterized in research as a non-redox, selective 5-lipoxygenase (5-LOX) inhibitor that suppresses leukotriene biosynthesis, with additional reported NF-κB/IKK pathway inhibition. This is mechanistic context, not a claim that it treats any disease.

2. What dose is used in research, and is generic resin the same as branded extracts?

Generic-extract osteoarthritis research typically uses standardized extract around 300–500 mg three times daily (~900–1500 mg/day), while AKBA-enriched branded extracts such as Aflapin and 5-Loxin have been studied at roughly 100–250 mg/day. These are not interchangeable: low-dose data applies only to the specific branded extract studied, not to generic resin powder. This is educational reference, not a dosing recommendation.

3. What does the strongest evidence show for joint comfort?

The most robust signal is in osteoarthritis. A meta-analysis of seven trials (545 patients) reported a VAS pain WMD of -8.33 and a WOMAC function WMD of -10.75 (Yu 2020, PMID 32680575), and a separate 9-RCT meta-analysis of 712 participants reported a VAS pain MD of -10.71 with the Aflapin subgroup showing larger effects (Dubey 2024, PMID 38365549). These are research findings in OA populations described, not a treatment claim.

4. Is boswellia an approved treatment or health-claim ingredient?

In the US it is a dietary-supplement ingredient under DSHEA, allowing only structure/function statements (e.g., joint health) with the FDA disclaimer; it is not an approved drug. The EU has no authorized EFSA health claim, Brazil regulates it as a traditional phytomedicine rather than a supplement, and China treats it as a TCM herbal material. This page reports research findings and is not medical advice.

Last evidence review: 2026-06-13

← Evidence library

Ask Agent Axor